These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 11361532)

  • 1. Neurex launches phase III program for SNX-111 for the treatment of chronic pain.
    AIDS Patient Care STDS; 1996 Oct; 10(5):311-2. PubMed ID: 11361532
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain.
    Brose WG; Gutlove DP; Luther RR; Bowersox SS; McGuire D
    Clin J Pain; 1997 Sep; 13(3):256-9. PubMed ID: 9303259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal ziconotide for chronic pain.
    Bonicalzi V; Canavero S
    JAMA; 2004 Oct; 292(14):1681-2; author reply 1682. PubMed ID: 15479926
    [No Abstract]   [Full Text] [Related]  

  • 4. Elan: ziconotide review focused on off-label uses.
    Narayana AK
    Am J Hosp Palliat Care; 2005; 22(6):408. PubMed ID: 16323709
    [No Abstract]   [Full Text] [Related]  

  • 5. The snail companies. Neurex Corporation & Cognetix Inc.
    Wells WA
    Chem Biol; 1998 Sep; 5(9):R235-6. PubMed ID: 9755372
    [No Abstract]   [Full Text] [Related]  

  • 6. Ziconotide. CI 1009, SNX 111.
    Drugs R D; 1999 Jan; 1(1):46-8. PubMed ID: 10565986
    [No Abstract]   [Full Text] [Related]  

  • 7. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain.
    Bowersox SS; Gadbois T; Singh T; Pettus M; Wang YX; Luther RR
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1243-9. PubMed ID: 8968347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide leads new class of chronic pain drugs.
    Garber K
    Nat Biotechnol; 2005 Apr; 23(4):399. PubMed ID: 15815650
    [No Abstract]   [Full Text] [Related]  

  • 9. Conus peptides and neuroprotection.
    Heading CE
    Curr Opin Investig Drugs; 2002 Jun; 3(6):915-20. PubMed ID: 12137413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the binding of omega-conopeptides to different classes of non-L-type neuronal calcium channels.
    Kristipati R; Nádasdi L; Tarczy-Hornoch K; Lau K; Miljanich GP; Ramachandran J; Bell JR
    Mol Cell Neurosci; 1994 Jun; 5(3):219-28. PubMed ID: 8087420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of SNX-111, a selective N-type calcium channel blocker, in rats and cynomolgus monkeys.
    Bowersox S; Mandema J; Tarczy-Hornoch K; Miljanich G; Luther RR
    Drug Metab Dispos; 1997 Mar; 25(3):379-83. PubMed ID: 9172958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ziconotide (Prialt) for chronic pain.
    Med Lett Drugs Ther; 2005 Dec 5-19; 47(1223-1224):103-4. PubMed ID: 16331245
    [No Abstract]   [Full Text] [Related]  

  • 13. The omega-conopeptide SNX-111, an N-type calcium channel blocker, dramatically ameliorates brain damage due to transient focal ischaemia.
    Zhao Q; Smith ML; Siesjö BK
    Acta Physiol Scand; 1994 Apr; 150(4):459-61. PubMed ID: 8036915
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential blockade of voltage-sensitive calcium channels at the mouse neuromuscular junction by novel omega-conopeptides and omega-agatoxin-IVA.
    Bowersox SS; Miljanich GP; Sugiura Y; Li C; Nadasdi L; Hoffman BB; Ramachandran J; Ko CP
    J Pharmacol Exp Ther; 1995 Apr; 273(1):248-56. PubMed ID: 7714772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A selective N-type Ca(2+)-channel blocker prevents CA1 injury 24 h following severe forebrain ischemia and reduces infarction following focal ischemia.
    Buchan AM; Gertler SZ; Li H; Xue D; Huang ZG; Chaundy KE; Barnes K; Lesiuk HJ
    J Cereb Blood Flow Metab; 1994 Nov; 14(6):903-10. PubMed ID: 7929655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of N- and P/Q-type calcium channels reduces the secondary heat hyperalgesia induced by acute inflammation.
    Sluka KA
    J Pharmacol Exp Ther; 1998 Oct; 287(1):232-7. PubMed ID: 9765342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of omega-conopeptides in conscious rats: mechanisms of action.
    Bowersox SS; Singh T; Nadasdi L; Zukowska-Grojec Z; Valentino K; Hoffman BB
    J Cardiovasc Pharmacol; 1992; 20(5):756-64. PubMed ID: 1280738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of recalcitrant pain in a pediatric acquired immunodeficiency syndrome patient.
    Anand A; Carmosino L; Glatt AE
    Pediatr Infect Dis J; 1993 Feb; 12(2):159-60. PubMed ID: 8426777
    [No Abstract]   [Full Text] [Related]  

  • 19. A consensus structure for omega-conotoxins with different selectivities for voltage-sensitive calcium channel subtypes: comparison of MVIIA, SVIB and SNX-202.
    Nielsen KJ; Thomas L; Lewis RJ; Alewood PF; Craik DJ
    J Mol Biol; 1996 Oct; 263(2):297-310. PubMed ID: 8913308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection in the rat lateral fluid percussion model of traumatic brain injury by SNX-185, an N-type voltage-gated calcium channel blocker.
    Lee LL; Galo E; Lyeth BG; Muizelaar JP; Berman RF
    Exp Neurol; 2004 Nov; 190(1):70-8. PubMed ID: 15473981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.